potential indications for glp-1 receptor agonists keep expanding and Diabetic Kidney Disease: A Call of Attention to Nephrologists GLP1-GIP receptor co-agonists: a promising
Description
The reason they are interesting for PMOS is simple: many women with PMOS have insulin resistance
doi: 10.3978/j.issn.2227-684X.2014.12.01
(3) Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets the TITRATETM study [PubMed Abstract] [Full Text HTML] [Full Text PDF]
A study in the Journal of the American Medical Association supported that view, along with one in the journal Diabetes, Obesity and Metabolism that found that after stopping semaglutide for one year, people had regained two-thirds of the weight they had lost
And the first GLP-1 agonist for obesity/weight loss was approved a full decade ago
